Literature DB >> 24703861

Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis.

Rohit Loomba1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24703861      PMCID： PMC4171196          DOI： 10.1016/j.cgh.2014.03.026

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  10 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 2.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease.

Authors:  Dawn M Torres; Christopher D Williams; Stephen A Harrison
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-23       Impact factor: 11.382

3.  Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.

Authors:  Z Permutt; T-A Le; M R Peterson; E Seki; D A Brenner; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-05-03       Impact factor: 8.171

4.  Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Elizabeth M Brunt; David E Kleiner; Kris V Kowdley; Naga Chalasani; Joel E Lavine; Vlad Ratziu; Arthur McCullough
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

5.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

6.  Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials.

Authors:  Rohit Loomba; Robert Wesley; Frank Pucino; T Jake Liang; David E Kleiner; Joel E Lavine
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-25       Impact factor: 11.382

7.  Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Authors:  J H Hoofnagle; M L Van Natta; D E Kleiner; J M Clark; K V Kowdley; R Loomba; B A Neuschwander-Tetri; A J Sanyal; J Tonascia
Journal:  Aliment Pharmacol Ther       Date:  2013-05-29       Impact factor: 8.171

8.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.

Authors:  Mazen Noureddin; Jessica Lam; Michael R Peterson; Michael Middleton; Gavin Hamilton; Thuy-Anh Le; Ricki Bettencourt; Chris Changchien; David A Brenner; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2013-10-17       Impact factor: 17.425

9.  Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

Authors:  Vlad Ratziu; Pierre Bedossa; Sven M Francque; Dominique Larrey; Guruprasad P Aithal; Lawrence Serfaty; Mihai Voiculescu; Liliana Preotescu; Frederik Nevens; Victor De Lédinghen; Gabriele I Kirchner; Pavel Trunecka; Stephen D Ryder; Christopher P Day; Jun Takeda; Klaudia Traudtner
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-12       Impact factor: 11.382

10.  Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.

Authors:  Thuy-Anh Le; Joshua Chen; Christopher Changchien; Michael R Peterson; Yuko Kono; Heather Patton; Benjamin L Cohen; David Brenner; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425
  10 in total
  2 in total

1.  Phenotypes of Chronic Hepatitis B in Children From a Large North American Cohort.

Authors:  Kathleen B Schwarz; Manuel Lombardero; Adrian M Di Bisceglie; Karen F Murray; Philip Rosenthal; Simon C Ling; Yona Keich Cloonan; Norberto Rodriguez-Baez; Sarah Jane Schwarzenberg; Jay H Hoofnagle; Jeffrey Teckman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-11       Impact factor: 2.839

2.  Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).

Authors:  Rohit Loomba; Claude B Sirlin; Brandon Ang; Ricki Bettencourt; Rashmi Jain; Joanie Salotti; Linda Soaft; Jonathan Hooker; Yuko Kono; Archana Bhatt; Laura Hernandez; Phirum Nguyen; Mazen Noureddin; William Haufe; Catherine Hooker; Meng Yin; Richard Ehman; Grace Y Lin; Mark A Valasek; David A Brenner; Lisa Richards
Journal:  Hepatology       Date:  2015-02-27       Impact factor: 17.425
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.